Through a genomic screening method known as CRISPR/CAS9 screening, Massey scientists—led by Anthony Faber and Jennifer Koblinski—identified a specific enzyme called UBA1 that revealed itself as an ideal therapeutic target in triple negative breast cancer. Using a novel UBA-inhibiting drug called TAK-243, they blocked the cellular function of UBA1 and effectively killed cancer cells in patient-derived breast tumors in mice.
Clairity Inc. received FDA De Novo authorization for CLAIRITY BREAST, a novel, image-based prognostic platform designed to predict five-year breast cancer risk from a routine screening mammogram. With this authorization, Clairity is planning to launch among leading health systems through 2025—propelling a new era of precision medicine in breast cancer.
